0

Aduro Biotech (ADRO) Closes Down Trial On Safety Issue For Main Drug

On Monday, Aduro Biotech (NASDAQ:ADRO) fell as much as 22% after the company announced that a patient tested positive for listeria. Due to this development the FDA had to place the clinical trials on a partial hold. The clinical trials… Continue Reading

0

Array Biopharma (ARRY) Announces Successful Phase 3 Results In Patients With Melanoma

On Monday, Array Biopharma (NASDAQ:ARRY) shares gained 80% after the company announced positive results in its phase 3 clinical trial treating patients with metastatic melanoma. More specifically the clinical trial met on the primary endpoint of the phase 3 study.… Continue Reading

0

Aurinia Pharmaceuticals (AUPH) Tumbles After Major Setback

On Monday, Aurinia Pharmaceuticals (NASDAQ:AUPH) announced positive phase 2b results in patients with lupus nephritis. The company was testing its drug Voclosporin in combination with standard of care — Roche (OTCMKTS:RHHBY) drug known as CellCept. While the trial results were positive the… Continue Reading

0

Cytrx Shares Fall 66% After Phase 3 Sarcoma Trial Failure

In pre-market trading, on July 12 2016, shares of Cytrx Corporation (NASDAQ:CYTR) fell by 66% as the company had announced that its Phase 3 trial treating sarcoma patients failed to meet the primary endpoint of the study. The phase 3 trial… Continue Reading

0

Juno Therapeutics (JUNO) Tanks 30% Pre-Market After FDA Halts Cancer Trial

On July 8, 2016 in pre-market trading, shares of Juno Therapeutics (NASDAQ:JUNO) are down 30% after the company announced that one its leukemia cancer trials has been halted due to two patient deaths. This pivotal trial, ‘ROCKET,’ was one that… Continue Reading